66
Participants
Start Date
December 19, 2023
Primary Completion Date
December 19, 2027
Study Completion Date
December 19, 2028
Tucatinib in Combination of Oral VP16 and trastuzumab
Combination of tucatinib-Oral VP16-trastuzumab
RECRUITING
Centre François Baclesse, Caen
RECRUITING
Centre Georges-François Leclerc, Dijon
RECRUITING
Centre CARIO-Hôpital Privé des Côtes d'Armor (HPCA), Plérin
SUSPENDED
Oncopole Claudius Regaud, Toulouse
SUSPENDED
Institut Du Cancer Montpellier, Montpellier
RECRUITING
Hôpital Privé du Confluent, Nantes
RECRUITING
Centre Oscar Lambret, Lille
SUSPENDED
Centre Jean Perrin, Clermont-Ferrand
RECRUITING
Institut Curie, Paris
NOT_YET_RECRUITING
Hopital Saint-Louis Ap-Hp Senopole, Paris
RECRUITING
CHU Amiens Picardie-Site Sud, Amiens
RECRUITING
Institut Sainte Catherine, Avignon
RECRUITING
Institut Curie, Saint-Cloud
Seagen Inc.
INDUSTRY
Institut Curie
OTHER